NEW YORK, Feb. 3, 2021 /PRNewswire/ -- AIkido Pharma Inc.
(Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr.
Scott T. Tagawa, M.D., M.S., FACP, a
Professor of Medicine and Urology at Weill Cornell Medicine and an
Attending Physician at New York-Presbyterian-Weill Cornell Medical
Center, has joined the Company's Scientific Advisory Board.
"Scott is a leading scholar in the field of oncology medicine
and research," commented Mr. Anthony
Hayes, CEO of AIkido. "His experience and expertise will be
of tremendous value as we further our efforts to develop
therapeutic treatments for cancer and leverage the technologies we
have licensed. Dr. Tagawa is also the principle investigator
for the targeted radiopharmaceutical therapy at Weil Cornell and
his addition to our advisory board demonstrates our support for
this innovative technology."
Dr. Scott T. Tagawa, MD, MS, FACP
is a Professor of Medicine & Urology at Weill Cornell Medicine,
and an Attending Physician at NewYork-Presbyterian – Weill Cornell
Medical Center. Dr. Tagawa earned his BS from Georgetown University. He received his MD at the
University of Southern California
School of Medicine and after completing his internship and
residency training there, he became Chief Resident. Subsequently,
he underwent fellowship training in Hematology and Medical
Oncology, being appointed Chief Fellow for his final two years.
In August 2005, Dr. Tagawa was
appointed Assistant Professor of Medicine at Mount Sinai School of
Medicine, serving as Associate Program Director for the Fellowship
Training Program. As Director of Genitourinary Oncology for the
Division of Hematology and Oncology and Director of Medical
Oncology for the Deane Prostate Health and Research Center, Dr.
Tagawa took the lead in developing genitourinary clinical
trials.
Dr. Tagawa was recruited to Weill Cornell Medical College in
2007. His research covers clinical and translational investigations
in genitourinary tumors and thrombosis in malignancy. As the
Medical Director of the Genitourinary Oncology Research Program,
Dr. Tagawa leads clinical trials in the areas of prostate, kidney
and bladder cancer as well as the prevention and treatment of
thrombosis with cancer. He specializes in drug development and
theranostics in prostate cancer. Dr. Tagawa also serves as
Associate Director of Clinical Research for the Division of
Hematology and Medical Oncology and leader of the Genitourinary
Disease Management Team of the Meyer Cancer Center. Dr. Tagawa is
the WCMC principal investigator for the Alliance for Clinical
Trials in Oncology (formerly CALGB), serving on the Board of
Directors and as a funded member of the Genitourinary Committee. He
is a member of the Clinical Practice Guidelines Committee of the
American Society of Clinical Oncology (ASCO).
Additionally, he serves on the editorial boards of many
journals, is a member of numerous national and international
medical and scientific societies and has been named on multiple
"top doctor" award lists.
About AIkido Pharma Inc.
AIkido Pharma Inc. was
initially formed in 1967 and is a biotechnology company with a
diverse portfolio of small-molecule anti-cancer
therapeutics. The Company's platform consists of patented
technology from leading universities and researchers and we are
currently in the process of developing an innovative therapeutic
drug platform through strong partnerships with world renowned
educational institutions, including The University of
Texas at Austin and Wake
Forest University. Our diverse pipeline of therapeutics includes
therapies for pancreatic cancer, acute myeloid leukemia (AML) and
acute lymphoblastic leukemia (ALL). In addition, we are constantly
seeking to grow our pipeline to treat unmet medical needs in
oncology. The Company is also developing a broad-spectrum
antiviral platform that may potentially inhibit replication of
multiple viruses including Influenza virus, SARS-CoV (coronavirus),
MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this
press release constitute "forward-looking statements" within the
meaning of the federal securities laws. Words such as "may,"
"might," "will," "should," "believe," "expect," "anticipate,"
"estimate," "continue," "predict," "forecast," "project," "plan,"
"intend" or similar expressions, or statements regarding intent,
belief, or current expectations, are forward-looking statements.
While the Company believes these forward-looking statements are
reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are based upon current estimates and assumptions and are
subject to various risks and uncertainties, including without
limitation those set forth in the Company's filings with the SEC,
not limited to Risk Factors relating to its business contained
therein. Thus, actual results could be materially different. The
Company expressly disclaims any obligation to update or alter
statements whether as a result of new information, future events or
otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-appoints-dr-scott-t-tagawa-md-to-scientific-advisory-board-301221230.html
SOURCE AIkido Pharma Inc.